Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Pharmacyclics

AbbVie and J&J file first non-cancer use for Imbruvica with FDA

AbbVie and J&J file first non-cancer use for Imbruvica with FDA $21bn it paid to purchase ibrutinib's original developer Pharmacyclics in 2015.

Resurgent Actelion catches J&J's eye

Resurgent Actelion catches J&J's eye That may now be changing, as it was rumoured to have been in the running for Pharmacyclics – eventually bought by AbbVie for $21bn – and said earlier this year it was open

Trial of AbbVie's Rova-T disappoints at ASCO

Trial of AbbVie's Rova-T disappoints at ASCO The company has been spending heavily on the acquisition of new assets, for example buying Pharmacyclics and its fast-growing blood cancer therapy Imbruvica (ibrutinib) for $21bn last year.

Deal Watch April 2016

Deal Watch April 2016 However within 6 months AbbVie announced the $21bn Pharmacyclics acquisition, won against competition from J&J.

AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal

AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal Last year, the company made a major bolt-on acquisition in oncology when it bought Pharmacyclics for $21bn, claiming ownership of fast-growing haematological cancer therapy Imbruvica (ibrutinib).

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...